Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOLIPANC: Neoadjuvant NAPOX in Hepatic Oligometastatic Pancreatic Cancer
NCT04617457Phase 2Recruiting
- Sponsor
- University of Cologne
- Start
- Oct 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of liposomal irinotecan in pancreatic adenocarcinoma (PDAC), sponsored by University of Cologne. Primary endpoint: Overall survival after R0/R1 resection at 24 months. Started Oct 2021; status: recruiting.
02
Drugs
liposomal irinotecan
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04617457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04617457.